Using four decades of FDA orphan drug designations to describe trends in rare disease drug development: substantial growth seen in development of drugs for rare oncologic neurologic and pediatric-onset diseases

摘要

The online version contains supplementary material available at 10.1186/s13023-021-01901-6.